10:54 AM EDT, 06/09/2025 (MT Newswires) -- Metsera ( MTSR ) said Monday its phase 1 trial of weight loss GLP-1 receptor candidate MET-233i showed an 8.4% mean placebo-subtracted weight loss on day 36 at a 1.2-milligram dosage.

The trial of 80 participants with overweight or obesity without type 2 diabetes was designed to assess the pharmacokinetics, efficacy, and safety of the drug candidate, the company said.

The drug demonstrated "favorable tolerability profile" with no instances of severe or serious adverse events, according to a statement.

The trial revealed "dose-linear pharmacokinetics with an observed half-life of 19 days," according to the company.

Metsera ( MTSR ) said it plans to leverage trial data to advance MET-233i as a monotherapy and in combination with MET-097i. It expects to report clinical data from its MET-034i in combination with MET-097i in late 2025.

Shares were up more than 17% in recent trading.

Price: 32.17, Change: +4.68, Percent Change: +17.02